GOSS Stock Forecast & Price Target

Gossamer Bio is attractive fundamentally because seralutinib offers a differentiated, inhaled add-on approach in PAH with anti-proliferative, anti-inflammatory, and anti-fibrotic properties that could complement existing vasodilators and activin-pathway therapy, while the TORREY and PROSERA data suggest a biologically plausible clinical signal extending beyond simple vasodilation into improved pulmonary vascular architecture. The company also appears to have a potentially broad commercial opportunity if FDA review is constructive, as management envisions use across patients who have cycled through ERAs, PDE5 inhibitors, sGC stimulators, prostacyclins, and sotatercept, plus earlier-line add-on, CTD-APAH, and possible sequencing or combination settings. Financially, GOSS had $57.0M in cash, cash equivalents, and marketable securities as of June 30, 2026, which was described as sufficient to fund operating and capital expenditures into 1Q27, and the exchange offer reduced total convertible debt to $84.1M while eliminating about $116M of principal, improving the balance-sheet runway ahead of the September NDA filing and subsequent FDA milestones.

Gossamer Bio is a clinical-stage biopharmaceutical company whose investment case remains fundamentally fragile because it depends heavily on seralutinib, a single lead asset for PAH, and that asset still faces meaningful regulatory and execution risk despite the planned NDA submission in September. The company’s own disclosures suggest the path to approval has already slipped to potentially ~3Q27, while the pre-NDA discussion indicates the central issue is not filing eligibility but the statistical significance and treatment-effect magnitude from Ph3 PROSERA, underscoring uncertainty around whether the pivotal data will satisfy regulators. Financially, GOSS ended 2Q26 with $57.0M in cash, and the 1-for-80 reverse stock split plus additional dilution from warrants tied to the June 2026 debt exchange offer and August 2026 private placement point to persistent shareholder dilution and weak capital structure support for the stock.